[Metabolic bone diseases : what's new in 2023].

The sequential effects of romosozumab and denosumab in osteoporosis are shown in real-life, while the mechanisms of post-denosumab rebound are reviewed extensively. A network meta-analysis confirms the superiority of anabolics vs anti-resorptives on fracture reduction, while the latter shown a reduction of mortality in a large population-based study. Fracture risk prediction by FRAXPlus is improved.

[Constitutional diseases of bone: clinical flags].

Constitutional diseases of bone form a heterogeneous group of rare diseases of varied phenotypic presentations with a vast genetic heterogeneity. Detected mostly in childhood, they may also be diagnosed in adulthood. Medical history, clinical examination as well as biological and radiological investigations may lead to the diagnosis, which should be confirmed genetically.

[Osteoporosis: what's new in 2022].

The year 2022 has seen numerous studies: questioning the usefulness of vitamin D, the effect of osteoporosis treatments on mortality, and the benefit of parathyroidectomy on fractures in primary hyperparathyroidism. The efficacy of romosozumab is diminished by the treatments prescribed before its introduction. Finally, and fortunately, promising new molecules are available in various countries for the treatment of rare bone diseases.

[Management of septic arthritis].

Native joint septic arthritis is a medical emergency requiring urgent joint drainage and antibiotic therapy. In the absence of an artificial joint or a foreign body, the « rheumatological approach » with repetitive arthrocentesis yields similar outcomes in the literature when compared to surgical drainage. Arthrocentesis could therefore be viewed as the preferential method of joint drainage as it is associated both with reduced morbidity for patients and decreased costs for the healthcare system.